ACCORD shows diminishing returns from intensive treatments

A new analysis of the ACCORD trial data suggests there is a ‘floor effect’, with additional intensive interventions on lipids, BP and glycaemia showing diminishing returns on cardiovascular risk in people with type 2 diabetes.

Findings from the study of more than 10,000 people with type 2 diabetes provided no support for intensifying lipid control by adding fenofibrate to a statin or intensifying glycaemic control (<6%) in patients who had ‘standard’ glycaemic control (HbA1C 7-7.9%) and were using a statin.

There was no cardiovascular or mortality